Log in to search using one of your social media accounts:


SMC recommends abatacept

The Scottish Medicines Consortium (SMC) has announced today that abatacept (Orencia®) has been accepted for use within NHS Scotland, in combination with methotrexate (MTX), as a first-line biologic agent for adults with rheumatoid arthritis (RA), after failure with two conventional DMARDs.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news

Related Links:

More News: Abatacept | Arthritis | Drugs & Pharmacology | Methotrexate | Orencia | Rheumatoid Arthritis | Rheumatology